Organic Active Ingredients TRIZ Cases

A 3,4-dihydroisoquinoline scaffold is tuned to strengthen PRMT5 inhibition while improving oral absorption and in vivo tumor suppression.

Using tocopherol or tocotrienol carriers, nasal benzodiazepine delivery speeds absorption and avoids oral metabolism and IV complexity.

Targeting viral helicase-primase with indolinyl compounds helps suppress herpesvirus replication, reduce shedding risk, and simplify dosing.

Modified Brefeldin A derivatives improve plasma exposure, half-life, solubility, and safety while preserving antitumor activity.

Novel substituted pyrazolo[3,4-d]pyrimidines inhibit Wee-1 while improving metabolic properties for broader anti-tumor use.

Efavirenz is repurposed to hinder alpha-synuclein transmission and aggregation, targeting synucleinopathy progression with fewer long-term side effects.

Novel small-molecule GLP-1R agonists replace injections with oral dosing while preserving efficacy and improving glucose tolerance.

Novel dipyridopyrazine integrase inhibitors suppress HIV replication with a single-agent approach that helps limit drug interactions and resistance.

Formula (I) compounds inhibit aberrant TNFα activity, improving treatment options for inflammatory and autoimmune disorders.

A solubilized apixaban carrier system in soft-gel capsules improves dissolution, content uniformity, stability, and oral bioavailability.

GLO1 inhibition raises methylglyoxal levels to reduce anxiety, depression, and epilepsy symptoms when conventional therapies fail.

Combining BCAAs with L-Alanine improves plasma and muscle uptake, helping maintain muscle mass and neuromuscular function.

Turbulent mixing of lipid and amikacin streams enables commercial-scale liposome production with stable particle size and at least 40% encapsulation.

A pH-responsive microcapsule shell blocks API release in the mouth, then dissolves in the stomach to improve pediatric palatability and dosing.

Systemic losartan dosing helps control TGF-β-driven fibrosis and skin inflammation in dystrophic epidermolysis bullosa without lowering blood pressure.

Selective CTSC inhibition with azacycloalkyl carbonyl cyclic amines helps limit neutrophil-driven tissue destruction in inflammatory disease.

Blood-based DNA repair enzyme activity helps predict which lung cancer patients are more likely to respond to immune checkpoint therapy.

Gold(III) compounds boost mitochondrial respiration and oxidative phosphorylation in intestinal epithelial cells to speed mucosal healing and reduce inflammation.

Selective 1,3,4-oxadiazole compounds inhibit HDAC6 while improving bioavailability and limiting broad HDAC side effects in therapy.

Small-molecule GCS inhibitors with indene or benzofuran moieties reduce glucosylceramide production for lysosomal storage disorders.

Cyclodextrin improves imatinib solubility and organoleptic properties, enabling inhaled delivery with high lung concentrations and fewer adverse reactions.

A high-surface-area biphasic excipient helps hydrophobic agents dissolve, partition into GI epithelium, and improve oral bioavailability.

Engineered AmphDI-derived polypeptides transfer unnatural sugars to AmdeB, enabling scalable C2′epiAmB production with lower synthesis complexity.

Engineered Type III-E CRISPR effectors combine modular domains and RNA guides to expand precise nucleic acid cleavage, insertion, and deletion.

Specific crystalline CFTR modulator forms improve stability, purity, and handling while supporting stronger CFTR channel function in cystic fibrosis.

Structural tuning of ribose-based GalNAc ligands improves ASGPR binding, liver delivery, and gene silencing in oligonucleotide drugs.

Electrosprayed levan-coated nanoclusters improve tumor penetration and trigger controlled doxorubicin release under ultrasound with lower systemic toxicity.

Combining orthosteric and allosteric EGFR inhibitors counters T790M and C797S resistance and improves tumor regression in EGFR-driven NSCLC.

Streamlined psilocybin and psilocin synthesis uses selective catalysts and optimized reaction steps to cut protection complexity, time, and cost.

Localized sustained-release prostate injection limits drug diffusion and systemic exposure while reducing BPH tissue with fewer dosing burdens.

Neutral liposomes use nucleic acid condensers, divalent cations, and cell-penetrating peptides to improve siRNA loading and cellular association.

Controlled 2-oxo-clopidogrel particle size and low-dose formulation enable stable oral release and clopidogrel bioequivalence before or after meals.

An enteric-coated oral C21 formulation prevents stomach degradation and preserves stable intestinal delivery for interstitial lung disease treatment.

Non-peptidyl somatostatin modulators target hormone secretion while reducing receptor desensitization, cost, and injection burden.

Thiazole compounds such as DJ-X-013 and DJ-X-025 reduce colitis by shifting MDSC, Th17, and NF-κB activity toward immune homeostasis.

Chemically modified B4GALT1 siRNA oligomers silence gene expression to lower insulin resistance and vascular risk markers.

Vegetable oil-derived polyols bind viral targets and disrupt bacterial metabolism, enabling broad-spectrum, low-cost infection inhibition.

Macrocyclic compounds stabilize misfolded CFTR to improve chloride transport, mucociliary clearance, and cystic fibrosis symptoms.

A continuous feeder and three-roller press enable direct compression of naproxen sodium tablets without granulation or glidants.

Engineered anellosomes encapsulate therapeutic genetic material to improve cell delivery while minimizing immune and inflammatory response.

Tuned cationic lipid structures improve nucleic acid transfection and sustained expression while lowering cytotoxicity and formulation complexity.

Localized inhalation of thrombin or protease inhibitors targets viral airway fibrin clotting to slow fibrosis progression.

Skin-metabolized Δ9-THC prodrugs improve systemic delivery by bypassing first-pass metabolism and overcoming poor skin absorption.

pH-dependent polymers and release-control materials replace hygroscopic acids to stabilize upadacitinib tablets and keep dissolution consistent.

By blocking CIC-1 chloride channels, these compounds restore neuromuscular transmission and help avoid the severe side effects of AChE inhibitors.

Electrosprayed particles enable high-concentration therapeutic suspensions with low viscosity and reduced aggregation, fragmentation, and charge variants.

Multi-wavelength DNIRA imaging improves AMD and pseudodrusen detection by separating drusen-like signals with higher diagnostic precision.

Structurally modified CBN analogs inhibit oxytosis and ferroptosis while protecting mitochondrial function without CB1/CB2 activation.

ALDH inhibitors expand dendritic and bone marrow cells ex vivo to boost CD8+ T cell responses and counter tumor immunosuppression.

Oral non-digestible capsules use hydrophilic cross-linked polymers to absorb GI fluid and toxins, helping reduce dialysis frequency.